Related Experiment Videos
Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis
M Jeyakumar1, T D Butters, R A Dwek
1Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, UK.
Neuropathology and Applied Neurobiology
|October 9, 2002
Summary
Mouse models reveal insights into the pathogenesis of glycosphingolipidoses, a group of paediatric neurodegenerative diseases caused by enzyme defects in glycosphingolipid (GSL) breakdown. These models aid in developing new therapeutic strategies.
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Paediatric neurodegenerative diseases, known as glycosphingolipidoses, stem from genetic defects in glycosphingolipid (GSL) metabolism.
- These disorders involve lysosomal accumulation of GSL substrates, particularly impacting the central nervous system (CNS).
- Current understanding of disease mechanisms and therapeutic options for these conditions remains limited.
Purpose of the Study:
- To review the insights gained from mouse models regarding the pathogenesis of glycosphingolipidoses.
- To discuss the progress in evaluating experimental therapies for these neurodegenerative disorders using animal models.
Main Methods:
- Utilizing genetically engineered mouse models that mimic human glycosphingolipidoses.
- Analyzing lysosomal storage, GSL substrate accumulation, and neuroinflammation in affected mouse models.
- Evaluating the efficacy of various experimental therapeutic interventions in these mouse models.
Main Results:
- Mouse models have elucidated key pathogenic pathways, including GSL accumulation and subsequent neurodegeneration.
- These models demonstrate the utility of studying enzyme deficiencies in GSL catabolism.
- Progress has been made in assessing the potential of novel therapeutic approaches, such as enzyme replacement and gene therapy, in preclinical settings.
Conclusions:
- Mouse models are invaluable tools for understanding the complex pathogenesis of paediatric glycosphingolipidoses.
- These models are crucial for advancing the development and preclinical evaluation of effective therapies for these devastating neurodegenerative diseases.